121 related articles for article (PubMed ID: 37981697)
21. Safety and Efficacy of Liver Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma After Segmental Transarterial Radioembolization.
Hardy-Abeloos C; Lazarev S; Ru M; Kim E; Fischman A; Moshier E; Rosenzweig K; Buckstein M
Int J Radiat Oncol Biol Phys; 2019 Dec; 105(5):968-976. PubMed ID: 31536781
[TBL] [Abstract][Full Text] [Related]
22. Radiofrequency ablation vs radiation therapy vs transarterial chemoembolization vs yttrium 90 for local treatment of liver cancer - a systematic review and network meta-analysis of survival data.
Chow R; Simone CB; Jairam MP; Swaminath A; Boldt G; Lock M
Acta Oncol; 2022 Apr; 61(4):484-494. PubMed ID: 34846988
[TBL] [Abstract][Full Text] [Related]
23. A retrospective comparative analysis of the effect of Y90-radioembolization on the survival of patients with unresectable hepatocellular carcinoma.
D'Avola D; Lñarrairaegui M; Bilbao JI; Martinez-Cuesta A; Alegre F; Herrero JI; Quiroga J; Prieto J; Sangro B
Hepatogastroenterology; 2009; 56(96):1683-8. PubMed ID: 20214218
[TBL] [Abstract][Full Text] [Related]
24. Thermal Ablation Versus Stereotactic Body Radiotherapy After Transarterial Chemoembolization for Inoperable Hepatocellular Carcinoma: A Propensity Score-Weighted Analysis.
Nabavizadeh N; Jahangiri Y; Rahmani R; Tomozawa Y; Geeratikun Y; Chen Y; Hung A; Degnin C; Farsad K
AJR Am J Roentgenol; 2021 Sep; 217(3):691-698. PubMed ID: 32997517
[No Abstract] [Full Text] [Related]
25. Stereotactic body radiation therapy combined with transcatheter arterial chemoembolization for small hepatocellular carcinoma.
Honda Y; Kimura T; Aikata H; Kobayashi T; Fukuhara T; Masaki K; Nakahara T; Naeshiro N; Ono A; Miyaki D; Nagaoki Y; Kawaoka T; Takaki S; Hiramatsu A; Ishikawa M; Kakizawa H; Kenjo M; Takahashi S; Awai K; Nagata Y; Chayama K
J Gastroenterol Hepatol; 2013 Mar; 28(3):530-6. PubMed ID: 23216217
[TBL] [Abstract][Full Text] [Related]
26. Comparison of outcomes between SBRT, yttrium-90 radioembolization, transarterial chemoembolization, and radiofrequency ablation as bridge to transplant for hepatocellular carcinoma.
Mohamed M; Katz AW; Tejani MA; Sharma AK; Kashyap R; Noel MS; Qiu H; Hezel AF; Ramaraju GA; Dokus MK; Orloff MS
Adv Radiat Oncol; 2016; 1(1):35-42. PubMed ID: 28799575
[TBL] [Abstract][Full Text] [Related]
27. Voxel-based dosimetry predicting treatment response and related toxicity in HCC patients treated with resin-based Y90 radioembolization: a prospective, single-arm study.
Kokabi N; Arndt-Webster L; Chen B; Brandon D; Sethi I; Davarpanahfakhr A; Galt J; Elsayed M; Bercu Z; Cristescu M; Kappadath SC; Schuster DM
Eur J Nucl Med Mol Imaging; 2023 May; 50(6):1743-1752. PubMed ID: 36650357
[TBL] [Abstract][Full Text] [Related]
28. Intra-arterial therapy of neuroendocrine tumour liver metastases: comparing conventional TACE, drug-eluting beads TACE and yttrium-90 radioembolisation as treatment options using a propensity score analysis model.
Do Minh D; Chapiro J; Gorodetski B; Huang Q; Liu C; Smolka S; Savic LJ; Wainstejn D; Lin M; Schlachter T; Gebauer B; Geschwind JF
Eur Radiol; 2017 Dec; 27(12):4995-5005. PubMed ID: 28677067
[TBL] [Abstract][Full Text] [Related]
29. Stereotactic body radiotherapy in hepatocellular carcinoma: patient selection and predictors of outcome and toxicity.
Loi M; Comito T; Franzese C; Dominici L; Lo Faro L; Clerici E; Franceschini D; Mancosu P; Reggiori G; Gallo P; Badalamenti M; Scorsetti M
J Cancer Res Clin Oncol; 2021 Mar; 147(3):927-936. PubMed ID: 32945972
[TBL] [Abstract][Full Text] [Related]
30. Review of Use of Y90 as a Bridge to Liver Resection and Transplantation in Hepatocellular Carcinoma.
Qadan M; Fong ZV; Delman AM; Gabr A; Salem R; Shah SA
J Gastrointest Surg; 2021 Oct; 25(10):2690-2699. PubMed ID: 34345997
[TBL] [Abstract][Full Text] [Related]
31. The challenge of inoperable hepatocellular carcinoma (HCC): results of a single-institutional experience on stereotactic body radiation therapy (SBRT).
Scorsetti M; Comito T; Cozzi L; Clerici E; Tozzi A; Franzese C; Navarria P; Fogliata A; Tomatis S; D'Agostino G; Iftode C; Mancosu P; Ceriani R; Torzilli G
J Cancer Res Clin Oncol; 2015 Jul; 141(7):1301-9. PubMed ID: 25644863
[TBL] [Abstract][Full Text] [Related]
32. Local control by salvage stereotactic body radiotherapy for recurrent/residual hepatocellular carcinoma after other local therapies.
Kibe Y; Takeda A; Tsurugai Y; Eriguchi T
Acta Oncol; 2020 Aug; 59(8):888-894. PubMed ID: 32216593
[No Abstract] [Full Text] [Related]
33. A Phase I/IIa Trial of Yttrium-90 Radioembolization in Combination with Durvalumab for Locally Advanced Unresectable Hepatocellular Carcinoma.
Lee YB; Nam JY; Cho EJ; Lee JH; Yu SJ; Kim HC; Paeng JC; Yoon JH; Kim YJ
Clin Cancer Res; 2023 Sep; 29(18):3650-3658. PubMed ID: 37459133
[TBL] [Abstract][Full Text] [Related]
34. Radiofrequency Ablation Versus Stereotactic Body Radiotherapy for Localized Hepatocellular Carcinoma in Nonsurgically Managed Patients: Analysis of the National Cancer Database.
Rajyaguru DJ; Borgert AJ; Smith AL; Thomes RM; Conway PD; Halfdanarson TR; Truty MJ; Kurup AN; Go RS
J Clin Oncol; 2018 Feb; 36(6):600-608. PubMed ID: 29328861
[TBL] [Abstract][Full Text] [Related]
35. Transarterial Radioembolization Treatment as a Bridge to Surgical Resection in Pediatric Hepatocellular Carcinoma.
Whitlock RS; Loo C; Patel K; Bista R; Goss JA; Heczey A; Khan O; Lopez-Terrada D; Masand P; Nguyen H; Mahvash A; Vasudevan SA; Kukreja K
J Pediatr Hematol Oncol; 2021 Nov; 43(8):e1181-e1185. PubMed ID: 33769387
[TBL] [Abstract][Full Text] [Related]
36. Neutrophil to Lymphocyte Ratio and Platelet to Lymphocyte Ratio in Hepatocellular Carcinoma Treated with Stereotactic Body Radiotherapy.
Park Y; Chang AR
Korean J Gastroenterol; 2022 Jun; 79(6):252-259. PubMed ID: 35746839
[TBL] [Abstract][Full Text] [Related]
37. Safety and efficacy of radioembolization with glass microspheres in hepatocellular carcinoma patients with elevated lung shunt fraction: analysis of a 103-patient cohort.
Das A; Riaz A; Gabr A; Ali R; Mora R; Al Asadi A; Mouli S; Lewandowski RJ; Salem R
Eur J Nucl Med Mol Imaging; 2020 Apr; 47(4):807-815. PubMed ID: 31502015
[TBL] [Abstract][Full Text] [Related]
38. Phase 2 study of stereotactic body radiotherapy and optional transarterial chemoembolization for solitary hepatocellular carcinoma not amenable to resection and radiofrequency ablation.
Takeda A; Sanuki N; Tsurugai Y; Iwabuchi S; Matsunaga K; Ebinuma H; Imajo K; Aoki Y; Saito H; Kunieda E
Cancer; 2016 Jul; 122(13):2041-9. PubMed ID: 27062278
[TBL] [Abstract][Full Text] [Related]
39. Comparison of Treatment Outcomes Between Thoracoscopic Surgery and Stereotactic Body Radiotherapy for Early-Stage Non-Small Cell Lung Cancer.
Tian Q; Zhao X; Zhang C; Tian N; Bian H
Technol Cancer Res Treat; 2024; 23():15330338231219369. PubMed ID: 38378004
[No Abstract] [Full Text] [Related]
40. Stereotactic body radiotherapy versus hepatic resection for hepatocellular carcinoma (≤ 5 cm): a propensity score analysis.
Sun J; Wang Q; Hong ZX; Li WG; He WP; Zhang T; Zhang AM; Fan YZ; Sun YZ; Zheng L; Duan XZ
Hepatol Int; 2020 Sep; 14(5):788-797. PubMed ID: 32886334
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
